Takeda's Dengue Vaccine Shows Long Lasting Protection and Simplified Logistics for Endemic Regions.

Takeda Pharmaceutical Co.'s dengue vaccine has shown long-lasting protection for seven years in a study involving 20,000 children and adolescents across eight dengue-endemic countries. The findings bolster confidence in the vaccine's two-dose regimen, which may not require additional doses in endemic regions. The vaccine generated $231 million in revenue for Takeda last fiscal year and remains the only dengue vaccine approved for broad use.